Sorry, you need to enable JavaScript to visit this website.

    New Pfizer Animal Health is Unveiled with Acquisition of Wyeth

    Addition of Fort Dodge Animal Health Products Diversifies and Enhances Pfizer’s Already Robust U.S. Portfolio

    (BUSINESS WIRE)--A new Pfizer Animal Health was unveiled last week as Pfizer's acquisition of Wyeth, including its subsidiary Fort Dodge Animal Health, was completed. Pfizer Animal Health is now the world’s leader in the discovery, development, manufacture and sales of veterinary vaccines and medicines for livestock and companion animals.

    The acquisition of many of Fort Dodge’s U.S. products allows Pfizer Animal Health to greatly diversify its U.S. portfolio, as well as broaden its offering in all animal health segments. Pfizer Animal Health now offers an enhanced portfolio in beef, dairy, and companion animals, as well as a redefined product line for swine, equine and poultry.

    “We’re extremely proud to offer our customers even more best-in-class and innovative products,” said Clint Lewis, president of U.S. Operations for Pfizer Animal Health. “The products, services and expertise we are gaining strengthen what is already a robust U.S. portfolio and will enhance our leading position in the animal health marketplace.”

    Here is a summary of Pfizer Animal Health’s new U.S. product portfolio:


    As the leader for beef and dairy animal health solutions, Pfizer will further enhance its position with the addition of FACTREL® (gonadorelin hydrochloride) and the proven and well-recognized pioneer line of SYNOVEX® implants. These products complement the current U.S. cattle portfolio that includes DRAXXIN® (tulathromycin), DECTOMAX®, EXCEDE® (ceftiofur crystalline free acid), EXCENEL® (ceftiofur hydrochloride), BOVI-SHIELD ® GOLD, LUTALYSE® (dinoprost tromethamine), ORBESEAL®, and SPECTRAMAST® (ceftiofur hydrochloride). Pfizer Animal Genetics also continues to explore opportunities to apply genomics technology to livestock health and management solutions.

    For the swine market, Pfizer Animal Health will offer a comprehensive range of solutions and services to strengthen its offering with the full line of SUVAXYN® brands, including SUVAXYN PCV-2 vaccine for circovirus. This addition rounds out an already broad product line that includes RESPISURE®, FLUSURE®, DRAXXIN®, and EXCEDE®.

    Already the world leader of in ovo technology, Pfizer Poultry Health will strengthen its position in the poultry industry with the addition of a broad range of poultry vaccines including POULVAC® and MATERNAVAC® IBD-Reo, a leading broiler-breeder vaccine.


    Joining an already industry-leading equine franchise that includes such established and well-respected brands as STRONGID® (pyrantel pamoate), DORMOSEDAN® (detomidine hydrochloride), and HYLARTIN® (sodium hyaluronate) are Fort Dodge’s WEST NILE INNOVATOR ®,FLU VAC INNOVATOR ® and QUEST®(moxidectin) and QUEST PLUS® (moxidectin/praziquantel).

    Companion Animals

    Top vaccine LYMEVAX® complements the current VANGUARD® canine vaccine line, and several anesthetic products help round out the small animal portfolio. They join current innovative offerings that include REVOLUTION® (selamectin), CERENIA™ (maropitant citrate), CONVENIA® (cefovecin sodium), RIMADYL® (carprofen) and SLENTROL® (dirlotapide).

    Pfizer Animal Health also announced today that all current U.S. pricing, product distribution, programs and policies for Pfizer Animal Health products, including the acquired Fort Dodge products, will remain in place through 2009.

    “Pfizer Animal Health is passionate about working hand-in-hand with our customers and partners to transform the care, health and well-being of animals,” Mr. Lewis said. “We continue to envision a future where animal health care providers, veterinarians and livestock producers look to Pfizer first to help them to run their practice or operation productively and profitably. With our newly expanded portfolio, value-added services and high-caliber talent, Pfizer is more focused than ever on providing relevant solutions to their animal care needs,” Mr. Lewis said.

    About Pfizer Animal Health

    Pfizer Animal Health, a business of Pfizer Inc (NYSE: PFE), is a world leader in discovering and developing innovative animal prescription medicines and vaccines, investing an estimated $300 million annually. Beyond the U.S., Pfizer Animal Health also supports veterinarians and their customers in more than 60 countries around the world. For more information on how Pfizer works to ensure a safe, sustainable global food supply with healthy livestock and poultry, or how Pfizer helps companion animals and horses to live longer, healthier lives, visit

    Global Animal Health Contact:
    Rick Goulart, 212-733-7457
    [email protected]
    U.S. Companion Animals/Equine:
    Deirdre O’Brien, 212-733-1488
    [email protected]
    U.S. Livestock:
    Ben Church, 212-733-6628
    [email protected]
    Global Poultry:
    Melinda Freson, 919-314-2698
    [email protected]

    Product Pipeline

    Learn about specific ways our research is leading to medicines and vaccines that will benefit patients around the world.

    Corporate Fact Sheet

    For more than 170 years, Pfizer has worked to make a difference for all who rely on us.

    Coronavirus Resources

    Learn about SARS-CoV-2, the coronavirus that causes COVID-19, what you can do to stay safe and prevent the spread, and our scientific efforts to help bring an end to the current global health crisis.

    Pfizer Logo

    Our logo is shorthand for everything Pfizer represents: an image that is instantly identifiable to our colleagues, patients, the external scientific community, and the public.

    Executive Leadership

    Meet the executive leadership team, our senior-most leadership and decision-making management body who focus on major financial, strategic, and operational decisions for the entire company.